3VFG: reference: In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors., Ahmed M, Goldgur Y, Hu J, Guo HF, Cheung NK, PLoS One. 2013 May 16;8(5):e63359. doi: 10.1371/journal.pone.0063359. Print 2013. PMID: 23696816 |
This OCA
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).